Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ7557560,53
KB646,5647-1,52
PKN64,4464,460,37
Msft242,21242,6-1,05
Nokia4,6164,6185-1,08
IBM146,75147,28-0,31
Mercedes-Benz Group AG63,7263,74-0,08
PFE49,4949,6-0,42
07.12.2022 14:23:28
Indexy online
AD Index online
select
AD Index online
 

  • 06.12.2022 11:07:22
Biotika (1BSL01AE.BV, Bratislava)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
23,00 -9,57 -2,20 690
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 07.12.2022
Popis společnosti
Obecné informace
Název společnostiBiotika as
Ticker1BSL01AE
Kmenové akcie:Ordinary Shares
Kmenové akcie:Ordinary Shares
RIC1BSL01AE.BV
ISINCS0009013453
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky30.06.2022
Počet zaměstnanců k 30.06.2022 201
Akcie v oběhu k 30.06.2022 700 000
MěnaEUR
Kontaktní informace
UliceSlovenska Lupca 566
MěstoSLOVENSKA LUPCA
PSČ976 13
ZeměSlovakia
Kontatní osoba 
Funkce kontaktní osoby 
Telefon421 484 368 111
Fax421484187060

Business Summary: Biotika as is a Slovakia-based joint stock company that specializes in biotechnology and production of pharmaceutical. The Company's activities are grouped into three main areas: biotechnological production of the substances of penicillin, chlorotetracycline and dextrans; production of final drug-forms for both human and veterinary use, including: penicillin and cephalosporin preparations, hormonal preparations, vitamin preparations; as well as production of premixes containing nutrition additives and medicated nutritive preparations. As of December 31, 2011, the Company operated two wholly owned subsidiaries, COV as Slovenska Lupca and Biotkika KLF as Slovenska Lupca.
Financial Summary: BRIEF: For the six months ended 30 June 2022, Biotika as revenues increased 35% to EUR6.5M. Net loss totaled EUR575K vs. income of EUR1M. Revenues reflect Substances segment increase of 31% to EUR5.3M, Services segment increase of 70% to EUR1.2M, Ghana segment increase from EUR0K to EUR1.5M, France segment increase from EUR0K to EUR780K. Net loss reflects Other Operating Income decrease of 97% to EUR21K (income).
Odvětvová klasifikace
TRBC2012Generic Pharmaceuticals
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries
SICCommercial Physical Research



  • Poslední aktualizace: 07.12.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Supervisory BoardMaria Kincesova-01.06.200301.06.2003
Chairman of the Management Board, General DirectorEmil Drlicka6406.09.200701.09.2007
Vice Chairman of the Supervisory BoardPetrus Winkelman-28.05.2004
Member of the Management Board, Economy DirectorMilan Mocik6101.05.200901.06.2006
Director of Legal DepartmentDenisa Chramcova-
Director of SalesAndrea Lilkova-
Director of Purchase and WarehousesViera Druskova-22.11.2011
Director of QualityJana Eervenakova-
Production DirectorSlavomir Geleta5301.01.200601.01.2006
Director of DevelopmentMaria Jakubcova6101.01.2006